Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)
Ratios

Aligos Therapeutics (ALGS) Accumulated Depreciation & Amortization (2021 - 2025)

Aligos Therapeutics' Accumulated Depreciation & Amortization history spans 5 years, with the latest figure at $12.7 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 7.89% year-over-year to $12.7 million; the TTM value through Dec 2025 reached $12.7 million, up 7.89%, while the annual FY2025 figure was $12.7 million, 7.89% up from the prior year.
  • Accumulated Depreciation & Amortization reached $12.7 million in Q4 2025 per ALGS's latest filing, up from $12.5 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $12.7 million in Q4 2025 to a low of $5.0 million in Q1 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $9.8 million, with a median of $10.6 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 59.25% in 2022, then rose 4.97% in 2025.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $7.3 million in 2021, then skyrocketed by 31.75% to $9.6 million in 2022, then increased by 12.41% to $10.8 million in 2023, then grew by 9.55% to $11.8 million in 2024, then grew by 7.89% to $12.7 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Accumulated Depreciation & Amortization are $12.7 million (Q4 2025), $12.5 million (Q3 2025), and $12.2 million (Q2 2025).